Close
Digital Health & Ai Innovation summit 2026
APE 2026

The 5th edition of the most established prostate cancer management congress in Europe

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Konica Minolta and deepc AI Partnership...

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed...

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand...

Novartis, which is a world-leading innovative medicines company, has...
Five years ago, in 2012, we first brought together the best of the best in prostate cancer management.

We had our core values in mind, values we sought to fulfil in the coming years. 
These core values:
  • Offer efficient education
  • Build community
  • Bring high-quality education
  • Bring together a multidisciplinary faculty
Looking back, we see these values tend to the right side. It goes around.
A multidisciplinary congress focussed around one topic and all past year’s highlights, brought to you by internationally renowned top experts where you can actively participate, discuss and network with like-minded prostate cancer professionals.
This year, at PROSCA 2017 , we will spend extra effort to highlight our core values even better.

Latest stories

Related stories

Konica Minolta and deepc AI Partnership Expands Exa Platform

Konica Minolta Healthcare Americas and deepc have formed a...

Medtronic Wins FDA Clearance for MiniMed Go Smart MDI System

Medtronic has received U.S. Food and Drug Administration (FDA)...

Novartis Plans its Fourth US Radioligand Therapy Facility

Novartis, which is a world-leading innovative medicines company, has...

Tempus-NYU Langone Collaboration Advances Precision Oncology

Tempus and NYU Langone Health have signed a multi-year...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »